Relapsed or Refractory Systemic Light Chain Amyloidosis
·MeSH: Amyloidosis
2 drugs in development·2 companies·1 clinical trial
Drug Pipeline by Phase
Phase 3(1)
| Drug | Company |
|---|---|
| ixazomib | X4 Pharmaceuticals, Inc (XFOR) |
Phase 4(1)
| Drug | Company |
|---|---|
| ixazomib | TAKEDA PHARMACEUTICAL CO LTD (TKPHF) |
Frequently asked questions
How many drugs are in development for Relapsed or Refractory Systemic Light Chain Amyloidosis?
BioSniper tracks 2 drugs in development for Relapsed or Refractory Systemic Light Chain Amyloidosis across 2 companies.
How many clinical trials target Relapsed or Refractory Systemic Light Chain Amyloidosis?
There are 1 clinical trial targeting Relapsed or Refractory Systemic Light Chain Amyloidosis tracked by BioSniper.
Deep-dive into Relapsed or Refractory Systemic Light Chain Amyloidosis
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis